Global Polycystic Ovarian Syndrome Treatment Markets, 2019-2024 Forecast Report -

DUBLIN--()--The "Polycystic Ovarian Syndrome Treatment Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

The global Polycystic Ovarian Syndrome Treatment market is expected to register a CAGR of around 4.8% over the forecast period, 2019-2024.

According to the Centers for Disease Control & Prevention (CDC), polycystic ovary syndrome (PCOS) is the most common cause of female infertility. Moreover, the progression of this condition can lead to metabolic abnormalities, which is likely to result in the development of type 2 diabetes, if the syndrome is not treated on time.

The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for a successful recovery. The increasing burden of PCOS and no targeted therapy for PCOS being available in the market creates a need to develop therapies to treat them. Thus it becomes one of the primary factors to drive the PCOS treatment market.

However, the side effects of symptomatic treatment drugs and lack of approved drugs directly targeting PCOS disease drugs act as among the major restraints to PCOS treatment market.

Key Market Trends

Laparoscopic Ovarian Drilling is Estimated to Hold the Largest Share by Surgery Over the Forecast Period

Laparoscopic Ovarian Drilling is among the most common surgeries performed by the doctors in critical conditions. Since the fertility problems faced by the women are quite predominant because of this condition, and response to medications weakens over time, the surgery performed via a thin microscope though the abdomen is majorly preferred across the geography.

Though this technique is largely adopted, but there is certain risk associated such as lower abdominal pain, bleeding, damage or scarring of the reproductive organs, and infection. In addition, the cost effective procedures drives the patients towards this surgical procedure for easy treatment of the disease. Thus, it is estimated to have major share, over the forecast period.

North America is Estimated to Have the Largest Share in the Global Market

The United States and Canada are highly advanced in terms of new technology procurement, early release of drugs in the market, better reimbursement policies and presence of multiple local and global biopharmaceutical companies. Along with this, there is a steady rise in medical tourism in these countries over the past two decades, which also approach these countries for one of the best medical treatments.

The need to ease the treatment and procedures has evolved significantly in past one decade which has given rise to several R&D investments and venture partners funding for pharmaceutical companies to invest into PCOS treatment in North America.

Competitive Landscape

The major market players are focusing on symptomatic treatments and several have their drugs in clinical trials, but not approved for marketing. There is a growing focus on surgeries, for which many medical devices are inclined towards. Some of the major players in the market are Bayer AG, Ferring BV, Merck KGaA, Novartis AG, and Teva Pharmaceutical Industries Limited, among others.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increased Burden of PCOS

4.2.2 Growth in Initiatives by Government and Private Players to Raise Awareness

4.3 Market Restraints

4.3.1 Adverse Effects Associated with Treatment

4.3.2 Lack of FDA Approved Drugs Specific to PCOS

4.4 Porter's Five Force Analysis


5.1 By Treatment

5.1.1 Drug Class Contraceptives Insulin-sensitizing Agent Antidepressants Anti-obesity Others

5.1.2 Surgery Ovarian Wedge Resection Laparoscopic Ovarian Drilling Other Surgeries

5.2 Geography

5.2.1 North America United States Canada Mexico

5.2.2 Europe France Germany United Kingdom Italy Spain Rest of Europe

5.2.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa

5.2.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 Abbott Laboratories

6.1.2 AstraZeneca PLC

6.1.3 Bayer AG

6.1.4 Bristol Myers Squibb

6.1.5 Ferring B.V.

6.1.6 Merck KGaA

6.1.7 Novartis AG

6.1.8 Pfizer Inc.

6.1.9 Sanofi

6.1.10 Teva Pharmaceutical Industries Limited


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900